https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race-en.html Drugnews｜藥時事 en 2026-10-17T00:00:00.000Z PharmaEssentia Won PV. Its Second War Is Against Merck's $1.35 Billion Pill https://drugnews.com.tw/articles/2026-10-17-pharmaessentia-china-et-approval-race.html Drugnews｜藥時事 zh-tw 2026-10-17T00:00:00.000Z 藥華藥賭贏 PV，第二戰撞上默沙東的 13.5 億美元！ https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription-en.html Drugnews｜藥時事 en 2026-10-16T00:00:00.000Z Alnylam’s Next Test: Winning the First Prescription https://drugnews.com.tw/articles/2026-10-16-attr-rnai-first-prescription.html Drugnews｜藥時事 zh-tw 2026-10-16T00:00:00.000Z Alnylam 的下一關：搶第一張處方 https://drugnews.com.tw/research/2026-10-17-research-tsmc-3q26-wafer-price-n2-dilution.htmlDrugnewszh-tw2026-10-17T20:00:00+08:00台積電Q3：晶圓只多3%，每片貴了13%